BioUtah News
-
Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform
Co-Diagnostics has announced that it has completed principal design work for a PCR test that would allow researchers…
-
Vertex Announces FDA Approvals for Expanded Use of Cystic Fibrosis Medicines
Vertex has announced FDA approval of eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF)…
-
Phoenix PharmaLabs Announces New Investment Offering with Netcapital
Phoenix PharmaLabs (Phoenix), a Utah company developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced…
-
State of Utah Announces Updated Plans for Vaccine Distribution
Today the State of Utah released updated plans for First Wave of Phase 2 COVID-19 Vaccine Distribution. Notably…
-
Medsential Offering an FDA EUA Approved COVID Point of Care Antibody Rapid Test
Medsential has announced that it is now offering COVID-19 IgM/IgG rapid antibody tests to point of care providers…
-
ELITech’s COVID, Flu, RSV Multiplex Test Receives CE Mark
ELITech Group recently announced its SARS-CoV-2 Plus Elite MGB Kit received CE marking and has been released. The…
-
SDP Oncology Presents Data Evaluating Alvocidib in Patients with Acute Myeloid Leukemia and Other Updates on Development Programs at ASH 2020
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently presented new data from the Phase 2 Zella 201 study…
-
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society’s Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been…
-
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2 of Cancer Study
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been…
-
Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test
Co-Diagnostics announced November 25 that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing…
-
Utah COVID-19 Small Business Quarantined Employee Grants
Utah continues to support the business community during the COVID-19 pandemic with its COVID-19 Small Business Quarantined Employee…
-
Braveheart Brings Healthcare to India’s Last Mile Community
These days we can all use uplifting news, so please check out this short story about how BraveHeart…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
